Search PubMed⌕ Search

Biomedical subjects

G Hayes

Publications and source records attributed to G Hayes.

49 records · Page 3Linked to original sources
PubMed1989

The major dopamine D2 receptor: molecular analysis of the human D2A subtype.

The structural diversity of the human D2 dopamine receptor was examined at the nucleic acid level. Sequence analysis of receptor cDNA clones isolated from human brain and pituitary libraries and polymerase chain reaction (PCR) analysis of rat brain RNA and human genomic DNA demonstrate the presence of a predominant D2 subtype, D2A. The D2A subtype differs from the D2B subtype, previously described in rat brain RNA, in that an additional 29 amino acids are present in the putative third cytoplasmic domain, a region thought to be important for coupling to different G-proteins. The demonstration of intron sequences flanking the DNA encoding the 29-amino-acid insertion suggests that the generation of two distinct D2 dopamine receptor subtypes may arise from alternative splicing of a common genomic sequence.

Amino Acid Sequence↗
PubMed1989

Identification of clinically significant skeletal muscle necrosis by single photon emission computed tomography.

Ischemia-reperfusion damage to skeletal muscle may cause serious local as well as systemic complications, its impact predominantly related to the quantity of ischemic muscle in the lower extremity. To date, there has been no noninvasive method of estimating that quantity. The authors used single photon emission computed tomography (SPECT) to quantify the volume of muscle that takes up technetium-99 pyrophosphate above a baseline threshold. Compared with the standard technique of staining slices of the muscle with nitroblue tetrazolium they found a close correlation using SPECT (r = 0.88, p less than 0.01, n = 19) in the canine model. In humans, this clinically applicable noninvasive technique may allow the surgeon to document accurately the extent of muscle necrosis in the lower extremity, to anticipate the impact of an ischemia-reperfusion injury and evaluate methods of reducing the extent of post-ischemic skeletal muscle necrosis.

Animals↗
PubMed1987

Natural History Study of Congenital Heart Defects.

A strategy designed to locate and recruit individuals who were part of a study in the 1960s of congenital aortic stenosis, pulmonary stenosis, and ventricular septal defect for purposes of a follow-up examination is presented. These individuals are now adults living throughout the United States and some foreign countries. The present study, referred to as NHS-2, is designed to bring the survivors back to one of six clinical centers for medical evaluation to study the long-term results of medical and surgical treatment of such patients.

Adult↗
PubMed1987

Comparison of sustained-release with standard tiaprofenic acid in the treatment of rheumatic diseases in general practice.

An open, parallel-group study was carried out to compare the efficacy and tolerance of a sustained-release capsule formulation of tiaprofenic acid at a dosage of 600 mg once daily with standard 300 mg tiaprofenic acid tablets given twice daily. Four hundred and eighty-five general practice patients with rheumatic disease requiring long-term non-steroidal anti-inflammatory drug therapy were included in the analysis. Patients were randomly allocated to receive, in a ratio of 3:1, either 2 X 300 mg sustained-release capsules at night or standard 300 mg tablets twice daily for a treatment period of 3 months. Pain, impairment of function and duration of morning stiffness were assessed at Week 0 (after a 3-day washout period) and at the end of Weeks 4, 8 and 12. Side-effects and compliance were also recorded at the end of Weeks 4, 8 and 12. Eighty-one (16.7%) patients withdrew from the study, with no significant difference in the withdrawal rates for the two treatment groups. Both treatment groups showed significant improvements clinically during tiaprofenic acid treatment; there were no significant differences between the two groups at Weeks 4, 8 or 12, nor were there any significant differences between the two treatment groups in the number of patients reporting side-effects at any of the assessments. In total, 36% of patients reported side-effects during the trial. The results indicate that both formulations are effective, well-tolerated treatments for rheumatic disease in general practice.

Adult↗
PubMed1986

Chronic intussusception due to antral myoepithelioma.

Intussusception was seen on abdominal sonography and computed tomography in a 15-year-old boy who presented with a 6-week history of weight loss, vomiting, abdominal pain, abdominal mass, and hyperamylasemia. Laparotomy revealed a chronic gastroduodenal intussusception, the lead point of which was an antral myoepithelioma, a rare entity in this age group.

Adolescent↗
PubMed1983

Single-blind comparison of penbutolol and long-acting propranolol in general practice.

A multi-centre, single-blind trial was carried out in general practice to compare the therapeutic efficacy, tolerance and compliance of penbutolol and long-acting propranolol, both given once daily, in patients with mild to moderate hypertension. Two hundred and twenty-two patients (111 patients in each treatment group) completed the 8-week treatment period. On completion, diastolic blood pressure was under control in 60% of patients receiving penbutolol and in 55% of patients receiving long-acting propranolol. Tolerance of the trial medications was good. At the final assessment, 88.3% of patients receiving penbutolol and 93.7% of patients receiving long-acting propranolol indicated no problems on direct questioning. Side-effects, as elicited from a 24-item symptoms list, were similar for both treatments and were generally minimal. Compliance was good in both treatment groups.

Adult↗
PubMed1981

Emergency seminar.

Explore the source record for details and available documents.

Disaster Planning↗
PubMedDate not supplied

Emerging infectious diseases in Alaska and the Arctic: a review and a strategy for the 21st century.

Emergence of new, previously unknown, and drug-resistant infectious diseases pose a major threat to global health. The emergence of infectious diseases in Alaska and the Arctic parallels the resurgence of infectious diseases worldwide. The Centers for Disease Control and Prevention has developed a strategy to revitalize the capacity to protect the public from emerging infectious diseases by improving four major public health activities: surveillance and response, applied research, infrastructure and training, and prevention and control. The plan targets high-priority emerging infectious disease problems and particular groups of people at increased risk. These target areas encompass a number of diseases of special concern in Alaska, such as drug-resistant Streptococcus pneumoniae infections, foodborne botulism, alveolar hydatid disease, viral hepatitis, Helicobacter pylori infections, Haemophilus influenzae type b bacteremia and meningitis, and infections of immunocompromised persons, pregnant women and newborns, and tourists. To address these and other emerging infectious disease issues, including the threat of bioterrorism in Alaska and the Arctic, future issues of Alaska Medicine will include updates on specific emerging infectious diseases for health care providers, clinical laboratory workers, and community public health professionals who form the front lines for recognizing, treating, and preventing emerging infectious diseases.

Alaska↗